Voyager Therapeutics (VYGR) EV to FCF (2015 - 2026)

Voyager Therapeutics has disclosed EV to FCF across 12 years of filings, most recently posting 3.77 for Q2 2026.

• In Q2 2026, EV to FCF fell 399.79% year-over-year to 3.77; the TTM figure through Jun 2026 stood at 0.81 (down 316.36% YoY), while the FY2025 annual figure was 0.26, up 88.62% from the prior year.
• EV to FCF came in at 3.77 for Q2 2026 at Voyager Therapeutics, down from 2.73 in the prior quarter.
• In the past five years, EV to FCF ranged from a high of 3.64 in Q1 2022 to a low of 111.64 in Q2 2023.
• Average EV to FCF over 5 years is 8.04, with a median of 2.29 recorded in 2024.
• Year-over-year, EV to FCF soared 613.11% in 2022 and plunged 2656.66% in 2023.
• Over 5 years, EV to FCF stood at 8.86 in 2022, then surged by 35.14% to 5.74 in 2023, then soared by 48.25% to 2.97 in 2024, then soared by 61.21% to 1.15 in 2025, then slumped by 226.81% to 3.77 in 2026.
• Per Business Quant data, the three most recent EV to FCF figures were 3.77 in Q2 2026, 2.73 in Q1 2026, and 1.15 in Q4 2025.